(Q30573851)

25 June 2017

title

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data (English)

1 reference

25 June 2017

Larsson G

1

1 reference

25 June 2017

Hallén B

series ordinal

2

1 reference

25 June 2017

Nilvebrant L

series ordinal

3

1 reference

25 June 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

25 June 2017

1 reference

25 June 2017

volume

53

1 reference

25 June 2017

issue

5

1 reference

25 June 2017

page(s)

990-998

1 reference

Voiding patterns and prevalence of incontinence in women. A questionnaire survey

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Current concepts in the treatment of disorders of micturition

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Pharmacologic treatment of incontinence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Tolterodine--a new bladder-selective antimuscarinic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Serum protein binding of tolterodine and its major metabolites in humans and several animal species

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900629-3

7 January 2021

10.1016/S0090-4295(98)00629-3

Identifiers

DOI

1 reference

25 June 2017

1 reference